March 28, 2020
Human Chorionic Gonadotropin Market

Human Chorionic Gonadotropin Market is gaining huge growth in upcoming years: Credence Research

The human chorionic gonadotropin market was valued at USD346.3 Mn in 2015, and is expected to reach USD533.7Mn by 2022, expanding at a CAGR of 6% from 2016 to 2022.

Treatment with infertility in both males and females is the major treatment area where HCG is commonly administered. Growing incidence of infertility in women, contributed to increased maternal age, lifestyle and other effects, hormonal days in men and increased incidence of oligospermia are key factors that have boosted demand for HCG drugs on the market. Demand for HCG is steady in developed markets in Europe and North America. On the other hand, increasing awareness among the general population and the development of healthcare infrastructure support the growth in demand for HCG drugs in emerging markets.

HCG supports the normal development of egg in the ovary and stimulates egg release during ovulation. It is also used for infertility treatment in women and to augment sperm count in men. HCG treatment is also given to young boys with undescended testicles. Hugh prevalence of both male and female infertility issues, increasing incidence of low sperm count and sperm density in men are key factors driving the market for HCG drugs. Most of the products currently available on the market are natural, i.e. urine-derived HCG. However, in view of the inconsistency of batch to batch in the purity of the product and the demand for a large amount of urine, recombinant production technology has emerged.

Get sample copy of report here:

North America is expected to be the largest and most potential regional market for human chorionic gonadotropin. North America constitutes regional markets of U.S.and Canada, the rising incidence of infertility cases, lifestyle effects and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin market. Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by2022. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centred in Japan, South Korea, China, and India.

The key players in human chorionic gonadotropin market are EMD Serono, Inc., Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius KabiUSA, LLC.

Based on therapeutic areas, the global human chorionic gonadotropin market categorized into:

  1. Female Infertility Treatment
  2. Oligospermia Treatment
  3. Cryptorchidism Treatment
  4. Others

Based on manufacturing technology, global human chorionic gonadotropin market categorized into:

  1. Natural Source Extraction
  2. Recombinant DNA Technology

Get sample copy of report here:

About Credence Research
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
(US/CANADA) Ph.: +1-800-361-8290

Leave a Reply

Your email address will not be published. Required fields are marked *